Thymosin alpha-1: what decades of human trials actually show

Thymosin alpha-1 has more human trial data behind it than almost any peptide people buy online, and it's a licensed prescription drug in some countries. That history cuts both ways. The early trials were small and often encouraging; the two largest and most rigorous ones, in sepsis (n = 1,106) and in hepatitis C (n = 552), found no benefit on their main outcome [7,10].

What it is

Thymosin alpha-1 is a 28-amino-acid peptide first isolated from calf thymus and sequenced in 1977 by Allan Goldstein’s group, who described it as a heat-stable, strongly acidic molecule that seemed to influence how T cells mature [1]. The thymus is the small gland behind the breastbone where T cells are trained, and the peptide was one of several fragments pulled out of a crude thymus extract called “fraction 5”.

A synthetic version, thymalfasin, is sold under the brand name Zadaxin. Its manufacturer, SciClone Pharmaceuticals, has described it as approved in parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East, mainly for hepatitis B and as a vaccine or chemotherapy add-on [3]. The US Food and Drug Administration noted in 2024 that it could not independently verify those approvals, and that the drug is not approved in the US, Japan or Europe, with Italy the exception [3].

How it's supposed to work is mostly worked out in animals and cell culture. In mice, synthetic thymosin alpha-1 switched on dendritic cells (the immune system’s scouts) through Toll-like receptor signalling, pushed the response towards the Th1 pattern that fights fungi and viruses, and protected transplanted mice from a lethal fungal lung infection [2]. That's a plausible mechanism for an “immune tuner”, but it's a mouse result and doesn't tell you what the drug does in a sick person.

The human evidence

The peptide has been tested in people for about four decades, across hepatitis, cancer, sepsis, HIV, COVID-19 and vaccine response. The pattern that keeps repeating: small or open-label studies look promising, then larger blinded trials shrink the effect or erase it.

Hepatitis B

One of the early randomised trials compared thymosin alpha-1 twice weekly with interferon alfa for six months in 33 people with a form of chronic hepatitis B [4]. Complete response (normal liver enzymes plus loss of viral DNA) at the end of treatment was 29.4% with the peptide and 43.8% with interferon; six months later it was 41.2% versus 25%. Neither difference was statistically significant, though the peptide was better tolerated, with local injection discomfort the only side effect [4]. Thirty-three patients can't settle anything.

The biggest hepatitis B trial came much later. In an open-label study, 690 people with hepatitis B cirrhosis took the antiviral entecavir with or without a year of thymosin alpha-1, and were followed for a median of 38 months [5]. Rates of liver decompensation, liver cancer or death didn't differ between groups. Liver cancer during the combination period was 1.7% versus 2.1%, which the authors framed as a “tendency”, but the primary endpoint was null [5].

A 2020 meta-analysis of seven randomised trials (n = 1,144, several published only in Chinese) found the add-on sped up the early response: viral DNA was undetectable more often at 24 weeks (risk ratio 1.91). By 48 to 52 weeks the advantage had gone [6]. Faster, then the same.

Hepatitis C

This one is clear. A placebo-controlled trial added thymosin alpha-1 or placebo to 48 weeks of peginterferon plus ribavirin in 552 people whose hepatitis C had already failed treatment [7]. Sustained viral response was 12.7% with the peptide and 10.5% with placebo (p = 0.407). The authors found a higher rate in the subgroup who completed all 48 weeks (41.0% vs 26.3%, p = 0.048), but that group selected itself, and they concluded the peptide “seems to play no role” in primary hepatitis C therapy [7]. Hepatitis C is now cured with oral direct-acting antivirals, which makes the question largely historical.

Melanoma

A five-arm trial randomised 488 people with metastatic melanoma to dacarbazine chemotherapy plus interferon, with or without one of three doses of thymosin alpha-1 [8]. Two peptide arms beat the prespecified response threshold (10 and 12 tumour responses versus 4 in the control arm). Median overall survival was 9.4 months with the peptide versus 6.6 months without (hazard ratio 0.80, p = 0.08), so the survival gain didn't reach significance [8]. This regimen predates modern immunotherapy and isn't a current option.

Sepsis

Sepsis is where the story is sharpest. The ETASS trial randomised 361 patients with severe sepsis in six Chinese hospitals to thymosin alpha-1 or usual care [9]. Deaths at 28 days were 26.0% versus 35.0%, relative risk 0.74 (95% CI 0.54 to 1.02). Whether that counts as significant depended on the test: p = 0.062 unstratified, p = 0.049 by log-rank. The trial was single-blind and had no placebo [9].

The same research group then ran TESTS, a double-blind, placebo-controlled phase 3 trial across 22 centres.

Prespecified subgroups hinted at benefit in people with diabetes and possible harm in those under 60 (hazard ratio 1.67), with a trend the other way in those 60 and over [10]. Subgroups from a null trial are ideas for the next trial, not findings. The trial was partly funded by SciClone, and several authors had received grants from the company [10].

A 2025 meta-analysis by overlapping authors pooled 11 randomised trials (1,927 patients) and found a lower death rate overall (odds ratio 0.73). Restricted to high-quality trials, the effect was no longer significant (OR 0.82, 95% CI 0.65 to 1.03), and the same happened for multicentre trials alone [11]. When the benefit lives in the smaller, weaker studies, that's usually the answer.

COVID-19

The COVID claim traces back mostly to one retrospective review of 76 severe patients in two Wuhan hospitals in early 2020 [12]. Those who happened to get thymosin alpha-1 died less often (11.1% vs 30.0%, p = 0.044) and had better T-cell counts. Doctors chose who got the drug, so the groups may simply have differed. A 2023 meta-analysis of nine studies (5,352 patients) found no effect on mortality (risk ratio 1.03, 95% CI 0.60 to 1.75), with very high heterogeneity, and concluded the data “do not support” its use in hospitalised adults [13]. Most of the included studies weren't randomised.

Vaccine response and HIV

In a pilot trial in 94 haemodialysis patients, adding thymosin alpha-1 to a pandemic H1N1 flu vaccine produced higher antibody titres at day 21 than vaccine alone [14]. There was no placebo arm, and the authors said larger studies were needed. In HIV, a 12-week open-label pilot in 20 people on antiretrovirals found no difference in CD4 or CD8 counts, though a marker of new T-cell output (sjTREC) rose [15].

Safety and side effects

This is the strongest part of the record. Across the trials above, serious drug-related harms were rare: TESTS found no difference in safety outcomes against placebo [10], the melanoma trial reported no extra toxicity [8], and ETASS recorded no serious drug-related adverse events [9]. The FDA’s 2024 review reached a similar reading, noting that doses of 1–16 mg under the skin for up to 12 months mostly weren't linked to significant adverse events, with local irritation, redness or discomfort at the injection site the commonest complaint [3].

The FDA did raise concerns that apply to compounded or unlicensed products. It judged the substance poorly characterised as a bulk ingredient, flagged a possible risk of immune reactions to the peptide itself (made worse by aggregation or impurities in concentrated solutions) and noted it had insufficient data on use alongside flu vaccines licensed in the US [3]. A licensed pharmaceutical and a vial of research-grade powder aren't the same product.

Legal and regulatory status

• United States: no approved product. In December 2024 the FDA told its compounding advisory committee that thymosin alpha-1 should not be added to the list of bulk substances pharmacies can compound from, citing characterisation, immunogenicity and lack of evidence of effectiveness. It also flagged a website advertising a compounded version as “FDA-approved”, which it isn't [3].
• Europe: not approved, except in Italy, according to the same FDA review [3].
• UK: we could find no UK marketing authorisation, so it isn't a licensed medicine here.
• Elsewhere: marketed as Zadaxin in a number of countries, chiefly in Asia, though the exact list rests on the manufacturer's own statements [3].

What we still don’t know

• Whether any group of sepsis patients (older people, people with diabetes) truly benefits. That needs a trial designed for the subgroup.
• Whether the early speed-up in hepatitis B response ever turns into fewer cases of liver cancer or death.
• What it does, if anything, in healthy people taking it for general “immune support”. No trial has tested that.
• How unlicensed products compare with the pharmaceutical version on purity and immune-reaction risk.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.

Free live webinar · Thursday 1 October · 7pm UK time

Join the next webinar: Introduction to Peptides

with Mitch O’Callaghan, ISSCA Peptide Therapist · Founder, Proper Protocols

Save my free placeHPR×Proper Protocols